AXSM Quote, Financials, Valuation and Earnings

BioVie has a net margin of -48.92% compared to Axsome Therapeutics's net margin of --. Axsome Therapeutics's return on equity of -309.19% beat BioVie's return on equity of --.

Axsome Therapeutics has a consensus price target of $176.35, signalling upside risk potential of 66.89%. On the other hand BioVie has an analysts' consensus of $5.50 which suggests that it could grow by 414.02%. Given that BioVie has higher upside potential than Axsome Therapeutics, analysts believe BioVie is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.456, which suggesting that the stock is 54.356% less volatile than S&P 500. In comparison BioVie has a beta of 1.180, suggesting its more volatile than the S&P 500 by 18.039%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioVie offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. BioVie pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are larger than BioVie quarterly revenues of --. Axsome Therapeutics's net income of -$59.4M is lower than BioVie's net income of -$7.1M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while BioVie's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 11.81x versus -- for BioVie. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of -48.92% compared to Axsome Therapeutics's net margin of -6.61%. Axsome Therapeutics's return on equity of -309.19% beat Integra Lifesciences Holdings's return on equity of -1.88%.

Axsome Therapeutics has a consensus price target of $176.35, signalling upside risk potential of 66.89%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 19.36%. Given that Axsome Therapeutics has higher upside potential than Integra Lifesciences Holdings, analysts believe Axsome Therapeutics is more attractive than Integra Lifesciences Holdings.

Axsome Therapeutics has a beta of 0.456, which suggesting that the stock is 54.356% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.765%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Axsome Therapeutics's net income of -$59.4M is lower than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 11.81x versus 0.64x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -48.92% compared to Axsome Therapeutics's net margin of -53.36%. Axsome Therapeutics's return on equity of -309.19% beat Madrigal Pharmaceuticals's return on equity of -49.57%.

Axsome Therapeutics has a consensus price target of $176.35, signalling upside risk potential of 66.89%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $421.93 which suggests that it could grow by 42.85%. Given that Axsome Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Axsome Therapeutics is more attractive than Madrigal Pharmaceuticals.

Axsome Therapeutics has a beta of 0.456, which suggesting that the stock is 54.356% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Axsome Therapeutics's net income of -$59.4M is higher than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 11.81x versus 20.28x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -48.92% compared to Axsome Therapeutics's net margin of 4.19%. Axsome Therapeutics's return on equity of -309.19% beat TG Therapeutics's return on equity of 19.78%.

Axsome Therapeutics has a consensus price target of $176.35, signalling upside risk potential of 66.89%. On the other hand TG Therapeutics has an analysts' consensus of $43.50 which suggests that it could grow by 30.36%. Given that Axsome Therapeutics has higher upside potential than TG Therapeutics, analysts believe Axsome Therapeutics is more attractive than TG Therapeutics.

Axsome Therapeutics has a beta of 0.456, which suggesting that the stock is 54.356% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $121.5M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Axsome Therapeutics's net income of -$59.4M is lower than TG Therapeutics's net income of $5.1M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 139.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 11.81x versus 13.89x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.